Trametinib and Hydroxychloroquine in Treating Patients with Pancreatic Cancer (THREAD)University of Utah / Novartis Pharmaceuticals
ClinicalTrials.gov Identifier: NCT03825289
Trametinib PubChem CID: 11707110
Investigators at the Huntsman Cancer Institute at the University of Utah are conducting a Phase I clinical trial to study the side effects and best dose of hydroxychloroquine when given together with trametinib (MEKINIST®, Novartis) in treating patients with pancreatic cancer that has spread to nearby tissue, lymph nodes, or other places in the body and cannot be removed by surgery.
See complete details, including study location(s), eligibility criteria, contact information, and study results (when available) at ClinicalTrials.gov.
Send email to firstname.lastname@example.org for information about submitting qualified clinical trials for sponsored posts on this blog.
The information on my blog is not intended as a substitute for medical professional help or advice but is to be used only as an aid in understanding current medical knowledge. A physician should always be consulted for any health problem or medical condition.